CCMQ

Discontinued Product

1238 has been discontinued.

View all NMDA Receptors products.
Description: Used to characterize GluN2B-containing NMDA receptors
Chemical Name: 2-Carboxy-3-carboxymethylquinoline
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for CCMQ

For use in conjunction with [3H]-homoquinolinic acid to characterize GluN2B (formally NR2B) containing NMDA receptors; selectively inhibits [3H]-homoquinolinic acid binding to non-NMDA sensitive sites.

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

Technical Data for CCMQ

M. Wt 231.21
Formula C12H9NO4
Storage Desiccate at +4°C
CAS Number 132623-44-0
PubChem ID 3337816
InChI Key IFXJDEHFADWURH-UHFFFAOYSA-N
Smiles OC(=O)CC1=C(N=C2C=CC=CC2=C1)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for CCMQ

Certificate of Analysis / Product Datasheet
Select another batch:

References for CCMQ

References are publications that support the biological activity of the product.

Brown et al (1998) [3H]-Homoquinolinate binds to a subpopulation of NMDA receptors and to a novel binding site. J.Neurochem. 71 1464 PMID: 9751179

View Related Products by Target

Keywords: CCMQ, CCMQ supplier, characterize, NR2B-containing, NMDA, receptors, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlu, Ionotropic, GluN2B, 1238, Tocris Bioscience

Citations for CCMQ

Citations are publications that use Tocris products.

Currently there are no citations for CCMQ.

Reviews for CCMQ

There are currently no reviews for this product. Be the first to review CCMQ and earn rewards!

Have you used CCMQ?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.